CymaBay Therapeutics
Presence
CymaBay Therapeutics is one of the...
CymaBay Therapeutics is a company listed under the stock ticker CBAY (US).
Acquisition, funding and merger involving CymaBay Therapeutics.
- Gilead Sciences has announced the acquisition of CymaBay Therapeutics (posted on February 15 2024).
Executives
View the org chart displaying its 16 main executives
Most searched biographies at CymaBay Therapeutics
- Sujal Shah, Director, President and Chief Executive Officer
- Robert Wills, Executive Chairman of the Board
- Caroline Loewy, Director
Popular executive movements at CymaBay Therapeutics
- Lewis Stuart, Chief Commercial Officer, will leave the company on Dec. 31, 2023 (posted on December 22 2023).
- Ben Kozub who is Vice President, Liver Franchise, will be promoted to Chief Commercial Officer on Dec. 31, 2023 (posted on December 22 2023).
Create your alert
to follow the executive moves at CymaBay Therapeutics.
Pharmaceuticals
CymaBay Therapeutics has 1,860 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).
Popular M&A news in Pharmaceuticals
- MedMen has filed for bankruptcy protection (posted on April 28 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (posted on March 23 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (posted on March 19 2024).
Popular contacts in Pharmaceuticals
News
Press releases by CymaBay Therapeutics
- CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update
- CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis
- CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update
- CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis
- CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis
- Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
- CymaBay Therapeutics to Participate in Upcoming Investment Conferences
- CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- New Published Data Demonstrates Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement in Primary Biliary Cholangitis in Phase 3 Post-Hoc Analysis of CymaBay's Seladelpar
- View more press releases Close
Social media about CymaBay Therapeutics
- CymaBay Therapeutics on Wikipedia, Google News & Yahoo Finance
- CymaBay Therapeutics on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Sujal Shah 
Call CymaBay Therapeutics at +1 510...
